|
Nymox Pharmaceutical Corporation Review of Safety Data for New Drug |
|
|
|
|
Saturday, 22 April 2006 |
Nymox Pharmaceutical Corporation Review of Safety Data for New Drug
 (NAMC) - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has reported that their new updated review of safety data for the company's ongoing multi-center Phase 2 trial of NX-1207 has revealed no serious drug side effects. NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH). NX-1207 has completed two earlier Phase 1 and 2 trials where the drug produced on average over 23% prostate shrinkage in 1 month with minimal side effects. Overall there have been no sexual side effects, and a better side effect profile compared to existing drugs. The symptomatic improvement in earlier trials reached 10 points on the BPH Symptom Score, which is far superior to available drugs, and compares to invasive and surgical treatments.
NAMC Newswire Note: The Wall Street to Main Street daily segment in its entirety will only be available to subscribers. Subscriptions are FREE , just go to www.namcnewswire.com and add your email address to receive the full segments as they are released. All email addresses are kept confidential and are only used for NAMC and not shared wtih third parties. To keep up to date with companies that we report on just register to receive Wall Street to Main Street in your email box every morning FREE. We feature companies that trade on the NYSE, AMEX, NASDAQ, OTCBB and Overseas, Keeping our readers informed daily. Just go to our site and register, it’s simple and free, www.namcnewswire.com . Also be sure to visit the NAMC radio at www.namcnewswire.com/namcradio for the latest reports, interviews and corporate updates featured on the NAMC Newswire.
|
|
NAMC News 
